Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030617 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL8083082 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL4752 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL13693410 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL13920783 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL6997217 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL14094837 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL4751 | 1.00 | HDAC4 (0.61) | HDAC4ALDH1A1SLC9A1SMN1; SMN2MAPK1 | |
| SCHEMBL8295172 | 0.83 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1SMN1; SMN2HPGD | |
| SCHEMBL4126470 | 0.83 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| WO-2017205964-A1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIVERSITé LAVAL (CA) | 2017-12-07 | — | — | WO | disclosed |
| EP-2788359-B1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RES TRIANGLE INST (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| WO-2010060215-A1 | 2-(N-SUBSTITUTED PIPERAZINYL) STEROID DERIVATIVES | UNIVERSITé LAVAL (CA) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | HDAC4 13/4885ALDH1A1 2293/4885SLC9A1 1356/4885 |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | NR5A1, HSD17B11, CYP17A1 | HDAC4 612/4885ALDH1A1 556/4885SLC9A1 4818/4885 |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | HSD17B11, HSD17B7, CYP19A1 | HDAC4 3243/4885ALDH1A1 668/4885SLC9A1 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.